|
Valent Technologies LLC agreement (Detail Textuals)
|
12 Months Ended | 1 Months Ended | 0 Months Ended | 0 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
USD ($)
|
Dec. 31, 2013
Warrants
|
Jan. 25, 2013
DelMar Pharmaceuticals, Inc
|
Sep. 12, 2010
Loan agreement
USD ($)
|
Sep. 12, 2010
Loan agreement
Valent Technologies, LLC
USD ($)
|
Dec. 31, 2013
Loan agreement
Valent Technologies, LLC
USD ($)
|
Dec. 31, 2012
Loan agreement
Valent Technologies, LLC
USD ($)
|
Feb. 03, 2011
Loan agreement
Valent Technologies, LLC
USD ($)
|
Feb. 01, 2012
Loan agreement
Valent Technologies, LLC
Warrants
|
|
| Agreement [Line Items] | |||||||||
| Consideration paid to acquire patent and prototype of drug product | $ 250,000 | ||||||||
| Lease amount of financing transaction | 2,000,000 | ||||||||
| Issuance of common shares to Valent for future royalty reduction (in shares) | 1,150,000 | ||||||||
| Loan amount | 250,000 | ||||||||
| Unsecured loan interest bearing rate | 3.00% | ||||||||
| Loan payable, including accrued interest | 272,372 | 264,352 | |||||||
| Accrued interest | 22,372 | 14,352 | |||||||
| Number of warrants issued | 200,000 | 500,000 | |||||||
| Exercise price of warrants (in Canadian dollars per warrant) | 0.50 | ||||||||
| Fair value of the contingent warrants | $ 89,432 | ||||||||